MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced the expansion of its executive leadership team. Marc Montserrat joins as Chief Business Officer of Deepcell, bringing two decades of experience at successful therapeutics, diagnostics and life sciences companies, including Roche and Genentech. The company also announced that Matt Posard, a 30-year life sciences industry veteran and former Illumina executive, will guide Deepcell’s leadership team as Chief Strategist, providing strategic guidance and executive-level support.

In his new role as CBO, Marc Montserrat is responsible for managing the company’s business development and providing leadership to create value for customers, partners and investors through strategic alignment and cross-functional execution. Before joining Deepcell, he was VP of Commercial Development at Omniome, and, prior to that role, he was International Business Leader for NIPT at Roche Diagnostics, where he helped scale the business from a startup at Ariosa Diagnostics to the sale and integration within Roche. Marc graduated with honors from the Wharton School with an MBA and from the Universitat Politècnica de Catalunya with a master’s degree in industrial engineering.

“I’m excited to join Deepcell and help drive the company’s mission to revolutionize cell isolation and classification by bringing cell morphology into the digital age,” said Montserrat. “Deepcell’s innovation is a breakthrough to contextualize and generate insights from cell morphology data through artificial intelligence. By identifying cell types in a hypothesis-free manner with high accuracy and isolating label-free, viable cells, Deepcell opens up new horizons for pharma and biotech companies, as well as academic and clinical researchers who are analyzing cells.”

As Chief Strategist, Matt Posard supports the executive team in charting Deepcell’s strategy, driving the company’s platform approach to address a wide breadth of applications relevant to cell biology. Posard continues to serve on the boards of Halozyme Therapeutics and Dermtech Inc., as well as sit on a number of private boards. Prior to his current work advising early stage companies, Posard was in key leadership positions at Illumina for nearly a decade. He has vast experience in launching novel products, especially instruments and consumables, and generating high growth and leading market share.

“I have a passion for helping advance start-up companies with disruptive technologies, such as Deepcell, and after what I have witnessed of their uniquely special approach to cell biology, I see Deepcell as having a real path to transform biological research, diagnostics and therapeutics in the future,” said Posard, who takes on the fractional executive role at a pivotal point. “Deepcell’s emergence from stealth mode recently comes at a perfect time when the converging of high speed, high resolution imaging with advanced microfluidics and AI gives us the opportunity to forever change research and applications of cell biology.”

Maddison Masaeli, co-founder and CEO of Deepcell, said, “We’re very pleased that Marc and Matt are part of our journey to take Deepcell to the next level. Their knowledge and collective experience will be highly valuable in bringing our AI-powered innovation to market and engaging with the life science and biomedical community to maximize the potential of our unique technology platform.”

For more information about Deepcell, please go to www.deepcell.com.

About Deepcell

Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Mountain View, CA. For more information, please visit deepcellbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005693/en/